The Commitment to Evidence
CROWN’s 360° Integrative Mind-Body Therapeutic Protocol draws on six therapeutic modalities with varying levels of established evidence. CBT has decades of validation. Yoga therapy and breathwork have growing evidence bases. EFT, TRE, and aromatherapy are in earlier stages of clinical investigation.
The integrated protocol — the specific combination, sequencing, and application of these six modalities to identity-based appearance discrimination — is new. CROWN does not claim that the protocol is a proven treatment. CROWN claims that it is a carefully designed clinical intervention, grounded in established therapeutic principles, that warrants rigorous evaluation.
That evaluation is underway.
The Three-Phase Validation Programme
CROWN’s clinical validation follows the standard progression used in psychotherapy research, adapted for the specific characteristics of the 360° Protocol and the population it serves.
Phase 1: Case Series
Design: Open-label case series with 20 participants.
Purpose: To establish the protocol’s feasibility, safety, and preliminary efficacy signal. Phase 1 answers the question: does the protocol produce measurable change in the expected direction, and is it acceptable to participants?
Participants: Adults living in Europe who self-report psychological distress related to identity-based appearance discrimination. Inclusion criteria include a minimum threshold score on the CROWN Discrimination Impact Scale (a measure developed specifically for this research) and willingness to engage with a multi-modality therapeutic programme over 12 weeks.
Measures: Validated psychometric instruments administered at baseline, mid-treatment (week 6), post-treatment (week 12), and three-month follow-up:
- PHQ-9 (Patient Health Questionnaire-9): Standard measure of depressive symptom severity. Nine items, validated across multiple populations and languages.
- GAD-7 (Generalised Anxiety Disorder-7): Standard measure of anxiety symptom severity. Seven items, widely used in clinical research and practice.
- Rosenberg Self-Esteem Scale: Ten-item measure of global self-esteem. Among the most widely used self-esteem instruments in psychological research.
- CROWN Discrimination Impact Scale: A measure developed by CROWN in consultation with the University of Geneva to capture the specific dimensions of psychological impact from identity-based appearance discrimination. Domains include: internalised appearance standards, conformity pressure, social avoidance, professional impact, and identity distress.
Additional measures may include physiological indicators (cortisol levels, heart rate variability) where feasible, and qualitative interviews to capture dimensions of experience not captured by standardised instruments.
Analysis: Within-subjects comparison of baseline to post-treatment scores, with effect size estimation. Qualitative thematic analysis of participant feedback. Identification of protocol elements that require modification before Phase 2.
Current status: Phase 1 is in preparation, with the study design under development in consultation with the University of Geneva, Faculty of Psychology and Educational Sciences.
Phase 2: Randomised Controlled Trial
Design: Three-arm randomised controlled trial with 60 participants (20 per arm).
Purpose: To establish whether the integrated 360° Protocol produces superior outcomes compared to (a) the primary modality alone (CBT) and (b) no treatment (waitlist control). Phase 2 answers the question: does the integration of multiple modalities add therapeutic value beyond what CBT provides on its own?
Arms:
- Arm A — Full 360° Protocol: All six modalities delivered according to the integrated protocol structure over 12 weeks.
- Arm B — CBT Only: Cognitive Behavioural Therapy alone, delivered over 12 weeks at matched intensity (same number of contact hours).
- Arm C — Waitlist Control: No treatment for 12 weeks, followed by access to the full protocol (ensuring all participants eventually receive the intervention).
Rationale for the comparator: CBT is the most strongly evidence-based individual modality within the protocol. The clinically important question is not whether the protocol is better than nothing (Phase 1 addresses this), but whether the multi-modality integration adds value beyond the primary modality alone. If the full protocol does not outperform CBT-only, the additional modalities may not be justified. If it does, the case for integration is empirically supported.
Measures: The same validated instruments as Phase 1, administered at the same time points. The larger sample size enables statistical comparison between arms with adequate power to detect medium effect sizes.
Analysis: Between-groups comparison at post-treatment and follow-up. Intent-to-treat analysis. Effect size estimation for the protocol versus CBT-only comparison. Secondary analyses of mediators (which outcomes are most affected by the additional modalities) and moderators (which participants benefit most from the integrated protocol).
Planned timeline: Phase 2 is planned following successful completion of Phase 1 and incorporation of any protocol modifications indicated by Phase 1 findings.
Phase 3: Multi-Site Replication
Design: Multi-site replication of the Phase 2 protocol across three European cities.
Purpose: To establish the protocol’s generalisability across cultural contexts, language groups, and practitioner teams. Phase 3 answers the question: do the results replicate when the protocol is delivered by different clinicians, in different languages, to participants from different cultural backgrounds?
Sites: Geneva (French-speaking), Paris (French-speaking, different national context), and London (English-speaking). The three sites represent distinct cultural, linguistic, and legal environments — differences that may affect both the experience of discrimination and the response to therapeutic intervention.
Rationale for multi-site design: Discrimination operates differently across cultural contexts. Grooming norms, legal frameworks, demographic composition, and the cultural meaning of hair all vary across European countries. A protocol validated in Geneva may not produce the same outcomes in London. Multi-site replication is the standard method for establishing cross-cultural validity.
Planned scope: The specific design of Phase 3 (sample size, number of arms, additional measures) will be informed by the results of Phase 2. If Phase 2 demonstrates clear superiority of the integrated protocol over CBT-only, Phase 3 may compare the full protocol against local standard-of-care. If the difference is modest, Phase 3 may focus on identifying which additional modalities contribute most to outcomes in different cultural contexts.
Ethical Oversight
All phases of the validation programme are conducted under institutional ethical review. Research involving human participants follows the principles of the Declaration of Helsinki and applicable Swiss and European Union regulations on clinical research.
Participants provide informed consent that clearly describes the protocol’s evidence status, the voluntary nature of participation, data handling procedures (GDPR and nDSG compliant), and the right to withdraw at any time without consequence. Participants who experience worsening symptoms during the study have access to safety protocols and referral to established mental health services.
Transparency
CROWN publishes the design, hypotheses, and planned analyses of each validation phase before data collection begins. This pre-registration practice reduces the risk of post-hoc analysis decisions that inflate apparent findings and allows the research community to evaluate CROWN’s methodology independently.
Results — whether positive, negative, or mixed — will be published in peer-reviewed journals and made available on CROWN’s publications page. CROWN does not selectively report findings that favour the protocol. The scientific value of validation research lies in honest reporting, regardless of the direction of results.
What This Means Now
The 360° Protocol is a clinical intervention in the early stages of formal validation. CROWN presents it accordingly — not as a proven treatment, but as a carefully designed programme that integrates established therapeutic approaches with emerging-evidence modalities, applied to a form of psychological harm (identity-based appearance discrimination) that has received insufficient clinical attention.
Individuals considering participation in the protocol should understand that they are contributing to the evidence base. Practitioners delivering the protocol are trained to communicate its evidence status honestly and to distinguish between what is established and what is under investigation.
This transparency is not a weakness. It is the foundation of CROWN’s scientific credibility.